Back to Search
Start Over
Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study
- Publication Year :
- 2017
-
Abstract
- Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL. Primary Funding Source: European Union Seventh Framework Programme.
- Subjects :
- Male
Lymphoma
Hepatitis B Surface Antigen
HIV Infections
medicine.disease_cause
Cohort Studies
10234 Clinic for Infectious Diseases
0302 clinical medicine
Risk Factors
HIV Infection
030212 general & internal medicine
Viral
Chronic
media_common
Incidence (epidemiology)
Hepatitis B Core Antigen
Lymphoma, Non-Hodgkin
Hazard ratio
virus diseases
General Medicine
Hepatitis C
Hepatitis B
Hepatitis B Core Antigens
Hepatitis Antibodie
030220 oncology & carcinogenesis
RNA, Viral
Female
hepatitis c and b
Cohort study
Human
Adult
medicine.medical_specialty
Anti-HIV Agents
Biomarkers
Hepatitis Antibodies
Hepatitis B Surface Antigens
Hepatitis B, Chronic
Hepatitis C, Chronic
Humans
Immunoglobulin G
Hepatitis C virus
Non-Hodgkin
610 Medicine & health
Settore MED/17 - MALATTIE INFETTIVE
03 medical and health sciences
Internal medicine
Internal Medicine
medicine
media_common.cataloged_instance
HIV HCV NHL HBV
European union
Hepatitis B virus
business.industry
Risk Factor
Anti-HIV Agent
Biomarker
10060 Epidemiology, Biostatistics and Prevention Institute (EBPI)
medicine.disease
digestive system diseases
2724 Internal Medicine
Immunology
RNA
Cohort Studie
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....08bc11af46d4bf86b6f2a327eed45582